LEO 130852A
Alternative Names: LEO130852ALatest Information Update: 28 Jul 2018
At a glance
- Originator LEO Pharma
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Skin-disorders in Germany (Topical, Gel)
- 12 Aug 2015 LEO Pharma completes a phase I trial in Skin disorders in Germany (NCT02392130)
- 06 Mar 2015 LEO Pharma plans a phase I trial for Skin disorders in Germany (NCT02392130)